|Articles|February 15, 2004

New drug application sought for combination IOP medication

Alcon is asking the FDA to approve a new drug application for its travoprost 0.004% plus timolol 0.5% fixed combination (TTFC) for the reduction of IOP in the treatment of glaucoma.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME